MX2009003417A - Metodo de inmunizacion contra los 4 serotipos de dengue. - Google Patents

Metodo de inmunizacion contra los 4 serotipos de dengue.

Info

Publication number
MX2009003417A
MX2009003417A MX2009003417A MX2009003417A MX2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A
Authority
MX
Mexico
Prior art keywords
dengue
serotype
dose
series
dengue serotypes
Prior art date
Application number
MX2009003417A
Other languages
English (en)
Spanish (es)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2009003417A publication Critical patent/MX2009003417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009003417A 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue. MX2009003417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (1)

Publication Number Publication Date
MX2009003417A true MX2009003417A (es) 2009-04-09

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003417A MX2009003417A (es) 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue.

Country Status (15)

Country Link
US (2) US7718358B2 (cg-RX-API-DMAC7.html)
EP (3) EP2077857B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090064593A (cg-RX-API-DMAC7.html)
CN (2) CN101553251B (cg-RX-API-DMAC7.html)
AR (1) AR063057A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007311792B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719849A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663885A1 (cg-RX-API-DMAC7.html)
FR (1) FR2906724B1 (cg-RX-API-DMAC7.html)
IL (2) IL197768A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009003417A (cg-RX-API-DMAC7.html)
TW (2) TWI406673B (cg-RX-API-DMAC7.html)
WO (1) WO2008047023A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901816B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
MX343172B (es) * 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2550298B1 (en) * 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US9637521B2 (en) * 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
TW201402143A (zh) * 2012-06-10 2014-01-16 Inviragen Inc 抗登革熱病毒疫苗之組成物及投藥方法
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
US20150196631A1 (en) * 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
KR102297300B1 (ko) * 2015-11-27 2021-09-02 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
EP3691681A1 (en) 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
PE20211545A1 (es) 2018-09-05 2021-08-16 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta
CN114555113A (zh) 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
NZ337522A (en) 1997-02-28 2001-02-23 St Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
EP1165128A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-2 virus vaccine
ES2322327T3 (es) 1999-03-26 2009-06-19 Walter Reed Army Institute Of Research Vacuna multivalente contra el virus del dengue.
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1263965B1 (en) 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP1402075B1 (en) 2001-05-22 2012-11-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003267937C1 (en) * 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
TW201336508A (zh) 2013-09-16
IL197768A0 (en) 2011-08-01
AR063057A1 (es) 2008-12-23
CN101553251A (zh) 2009-10-07
EP2077857B1 (fr) 2013-11-20
BRPI0719849A2 (pt) 2014-04-29
US7718358B2 (en) 2010-05-18
CN101553251B (zh) 2013-05-22
CA2663885A1 (en) 2008-04-24
CN103285386A (zh) 2013-09-11
EP2526965A1 (fr) 2012-11-28
EP2077857A2 (fr) 2009-07-15
KR20090064593A (ko) 2009-06-19
AU2007311792B2 (en) 2013-05-02
FR2906724A1 (fr) 2008-04-11
TW200826959A (en) 2008-07-01
WO2008047023A2 (fr) 2008-04-24
WO2008047023A3 (fr) 2008-10-23
FR2906724B1 (fr) 2009-03-20
JP2010505801A (ja) 2010-02-25
JP5269796B2 (ja) 2013-08-21
TWI406673B (zh) 2013-09-01
EP2526964A1 (fr) 2012-11-28
IL224572A (en) 2014-06-30
AU2007311792A1 (en) 2008-04-24
ZA200901816B (en) 2010-06-30
US20080085288A1 (en) 2008-04-10
US20100270202A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
MX2009003417A (es) Metodo de inmunizacion contra los 4 serotipos de dengue.
MY169275A (en) Method of immunization against the four serotypes of dengue
MY180698A (en) Immunization protocol against the 4 dengue serotypes
NO20072733L (no) Doseformer
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
TW200612987A (en) Combination treatment for non-hematologic malignancies
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
JP2007508326A5 (cg-RX-API-DMAC7.html)
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
MY153290A (en) Multivalent avian influenza vaccines
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
PH12022550261A1 (en) Methods for preventing dengue and hepatitis a

Legal Events

Date Code Title Description
FG Grant or registration